# Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma

> **NCT01269437** · PHASE2,PHASE3 · UNKNOWN · sponsor: **NovaMed Pharmaceuticals Inc.** · enrollment: 332 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide dry powder inhaler

## Key facts

- **NCT ID:** NCT01269437
- **Lead sponsor:** NovaMed Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2011-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01269437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01269437, "Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01269437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*